نتائج البحث - Haihong Shi
- يعرض 1 - 2 نتائج من 2
-
1
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of <scp>COVID</scp>‐19, in Subjects With Renal Impairment حسب Sima S. Toussi, Joel M. Neutel, J. Navarro, Richard Alfred Preston, Haihong Shi, Olga Kavetska, Robert R. LaBadie, Michael Binks, Phylinda L. Chan, Neil Demers, Brian Corrigan, Bharat Damle
منشور في 2022Artigo -
2
Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir حسب Ravi Shankar Prasad Singh, Sima S. Toussi, Frances Hackman, Phylinda L. Chan, Rohit Rao, Richard Allen, Lien Van Eyck, Sylvester Pawlak, Eugene P. Kadar, Frances Clark, Haihong Shi, Annaliesa S. Anderson, Michael Binks, Sandeep Menon, Gianluca Nucci, Arthur Bergman
منشور في 2022Artigo
أدوات البحث:
موضوعات ذات صلة
Antiretroviral therapy
Internal medicine
Medicine
Pharmacokinetics
Pharmacology
Ritonavir
Viral load
Virology
Virus
2019-20 coronavirus outbreak
Adverse effect
Clinical trial
Coronavirus Infections
Coronavirus disease 2019 (COVID-19)
Disease
Dosing
Infectious disease (medical specialty)
Outbreak
Protease inhibitor (pharmacology)
Regimen
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Tolerability